ICH E6(R2) Section 5 Sponsor Obligations

Under ICH E6(R2) Good Clinical Practice, the sponsor — “the individual, company, institution, or organization taking responsibility for the initiation, management, and/or financing of a trial” — carries a distinct, itemized set of obligations laid out in Section 5 of the guideline. These are separate from the investigator’s obligations (Section 4) and the IRB/IEC’s obligations (Section 3). A sponsor obligation, in the operational sense used here, is any duty Section 5 assigns by default to the sponsor and that the sponsor retains unless it is transferred to a Contract Research Organization (CRO) in writing under Section 5.2.

Operational definition

An activity counts as an “ICH E6(R2) Section 5 sponsor obligation” if it meets both of the following:

• It falls under one of the numbered Section 5 subsections (5.0 through 5.23) rather than Section 3 (IRB/IEC) or Section 4 (investigator).
• Default responsibility sits with the sponsor unless explicitly and specifically transferred in writing to a CRO — a general statement that “all obligations are transferred” is only valid for a full transfer; a partial transfer must itemize which specific obligations move, and anything not itemized in writing is deemed retained by the sponsor.

The itemized obligations

Section 5 groups sponsor obligations into the following functional areas (subsection numbers as commonly cited in GCP training and regulatory-affairs references; treat exact numbering as subject to confirmation against a primary ICH PDF before quoting verbatim in a regulatory submission):

• 5.0 Quality management — a risk-based quality management system built around identifying critical-to-quality (CtQ) factors, evaluating and controlling risk (including predefined quality tolerance limits, or QTLs, for a small number of trial-critical parameters), and documenting root-cause investigation when a QTL is breached. This subsection was added in the 2016 R2 addendum.
• 5.1 Quality assurance and quality control — implementing and maintaining systems (SOPs, training, QA audits) to ensure the trial is conducted and data generated, documented, and reported in compliance with the protocol, GCP, and applicable regulatory requirements.
• 5.2 Contract research organizations (CROs) — the sponsor may transfer any or all trial-related duties to a CRO, but ultimate responsibility for trial data quality and integrity always remains with the sponsor; any transfer must be specified in writing, and the sponsor must maintain oversight of everything performed on its behalf, including further subcontracting by the CRO. See CASRAI’s Contract Research Organization (CRO) entry and the Sponsor vs. CRO comparison for how this obligation plays out in practice.
• 5.5 Trial management, data handling, and recordkeeping — using qualified staff, adequately handling and storing trial data (including any electronic data handling systems, which must be validated), and maintaining essential documents.
• 5.6 Investigator selection — the sponsor is responsible for selecting investigators/institutions qualified by training and experience, and for providing them the protocol and an up-to-date Investigator’s Brochure.
• 5.8 Compensation to subjects and investigators — where required by applicable regulation, providing insurance or indemnifying the investigator/institution against trial-related claims (excluding claims arising from malpractice or negligence), and addressing costs of treating subjects for trial-related injury.
• 5.14 Supplying and handling investigational product(s) — confirming appropriate approvals exist before shipment, ensuring site-level written procedures for receipt, storage, dispensing, retrieval, and return/destruction, and maintaining systems and records covering delivery, shipment, receipt, disposition tracking, and recall.
• 5.16–5.18 Safety information, adverse event reporting, and monitoring — ongoing safety evaluation, expedited/periodic safety reporting to investigators, IRBs/IECs, and regulators, and monitoring trial conduct at a level and intensity appropriate to the trial’s objective, design, complexity, and risk (the basis for risk-based monitoring). Monitoring reports must be submitted to the sponsor in a timely manner with sufficient detail for follow-up.
• 5.19 Audit — a systematic, independent examination of trial-related activities and documents, separate from routine monitoring, conducted by auditors independent of the clinical operations team (see Inspection Readiness).
• 5.20 Noncompliance — identifying noncompliance by an investigator, staff, or the sponsor’s own personnel with the protocol, SOPs, GCP, or applicable regulatory requirements, and taking prompt corrective/preventive action; serious or persistent noncompliance can trigger termination of the investigator’s/institution’s participation and notification to regulators.
• 5.21 Premature termination or suspension of a trial — systems for promptly notifying investigators, IRBs/IECs, and regulatory authorities if a trial is terminated or suspended, with the reason clearly explained.
• 5.23 Multicenter trials — for trials run at more than one site, ensuring investigators conduct the trial in strict compliance with a single protocol agreed with the sponsor, and putting in place systems (harmonized case report forms, coordinating-investigator arrangements) to keep conduct comparable across sites.

Worked examples

Example 1 — CRO delegation letter. A sponsor contracts a CRO to run site monitoring and safety-database management for a Phase III trial. The delegation is documented in a written agreement itemizing exactly those two functions (Section 5.2). The sponsor retains everything not itemized — including ultimate responsibility for data quality — and remains the party a regulator would hold accountable if monitoring or safety reporting is deficient, even though the CRO performed the work.

Example 2 — quality tolerance limit breach. A sponsor’s quality management plan (Section 5.0) sets a predefined QTL for the rate of major protocol deviations across sites. When enrollment data show the limit breached at two sites, the sponsor’s quality system triggers a documented root-cause investigation and corrective action plan — this is a sponsor obligation under 5.0, independent of any monitoring the CRO performs under a separate delegation.

Counter-example

Obtaining and documenting a trial participant’s informed consent is not a Section 5 sponsor obligation — it is an investigator obligation under Section 4.8. A sponsor may support consent-form development or provide a template, but the duty to ensure consent is properly obtained, documented, and re-consented when the protocol changes sits with the investigator/institution at the site, not the sponsor. Similarly, reviewing and approving the protocol and informed consent materials before a trial starts is an IRB/IEC obligation under Section 3, not a sponsor one.

How this differs from CASRAI’s other GCP content

CASRAI’s Good Clinical Practice (GCP) guide explains the overall regulatory standard and who GCP applies to in general terms. The Sponsor vs. CRO comparison contrasts the two entity types at a structural level — what each is, who holds the IND/IDE, how delegation works. This entry is narrower and more specific than either: it itemizes the actual numbered Section 5 subsections that make up “what a sponsor is responsible for,” which neither the guide nor the comparison enumerates in full.

Related terms

• Contract Research Organization (CRO)
• Clinical Research Associate (CRA)
• Risk-Based Monitoring (RBM)
• Risk-Based Quality Management (RBQM)
• Inspection Readiness
• Good Clinical Practice (GCP) guide
• Sponsor vs. CRO comparison